BioPharma Resources

Drug Trial Radar · NCT01646385

Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry

Long-term Safety and Efficacy of Etanercept in a UK Observational Cohort Study - a Retrospective Database Analysis of British Society of Rheumatology Biologics Registry (BSRBR) Data

Last checked: Nov 19, 2026Latest source record: Aug 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

6,393

Actual

Start

Feb 2012

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 20, 2012

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the rates of serious adverse events and death in adult rheumatoid arthritis patients treated with etanercept over the long-term in real-life clinical practice. It will also assess whether there is any difference in the rate of serious adverse events in patients trated with etanercept in comparision to patients treated with conventional disease-modifying anti-rheumatic drugs (DMARDs). The study will in addition quantify the efficacy of etanercept in this population by assessing the rates of important clinical outcomes such as changes in disease activity and disability/functioning.

Conditions

  • Rheumatoid Arthritis

Interventions

  • etanerceptDrug

    use as per routine clinical practice

  • non-biologic anti-rheumatic drugsDrug

    use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Crude Incidence Rate of MalignancyTime frame: Baseline up to last follow-up, assessed every 6 month for first 3 years and thereafter annually up to 10 years
  2. Crude Incidence Rate of Lymphoproliferative Malignancy (LM)Time frame: Baseline up to last follow-up, assessed every 6 month for first 3 years and thereafter annually up to 10 years
  3. Crude Incidence Rate of Serious InfectionsTime frame: Baseline up to last follow-up, assessed every 6 month for first 3 years and thereafter annually up to 10 years
  4. Crude Incidence Rate of Other Serious Adverse EventsTime frame: Baseline up to last follow-up, assessed every 6 month for first 3 years and thereafter annually up to 10 years
  5. Crude Incidence Rate of All-Cause MortalityTime frame: Baseline up to last follow-up, assessed every 6 month for first 3 years and thereafter annually up to 10 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.